Ferumoxytol (Rienso®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013000693
English
Authors' recommendations:
Ferumoxytol (Rienso®) is recommended as an option for restricted use within NHS Wales. Ferumoxytol (Rienso®) should only be used for the intravenous treatment of iron deficiency anaemia in non-haemodialysis dependent adult chronic kidney disease patients when oral iron is ineffective or cannot be used. Ferumoxytol (Rienso®) is not recommended for use within NHS Wales outside of this subpopulation of patients. The diagnosis of iron deficiency must be based on appropriate laboratory tests.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/145
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.